相关实验视频
Updated: Sep 13, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
22.0K
在中高风险肺栓塞中比较半剂量阿尔特和LMWH:单中心观察性研究
Ömer Selim Selim Unat1, Pervin Korkmaz2,3, Akın Çinkooğlu2
1Dr. Suat Seren Göğüs Hastalıkları Hastanesi, Izmir, Turkey. unatomerselim@gmail.com.
概括
半剂量阿尔特等改善了中高风险肺栓塞 (PE) 患者的氧化和临床状态,显示死亡率低于LMWH,尽管在统计学上并不显著. 需要进一步的研究才能得出关于血栓消毒药物治疗有效性和安全性的最终结论.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 关键护理医学 关键护理医学
背景情况:
- 对于中高风险的肺栓塞 (PE) 进行血栓缓解疗法是有争议的.
- 这项研究将半剂量高高与PE患者的LMWH (乙诺沙巴林) 进行比较.
研究的目的:
- 为了评估半剂量高高剂量高剂量中等风险PE中高剂量高剂量高剂量高剂量高剂量高剂量的疗效和安全性.
- 评估一个月和一年的死亡率.
- 分析二次结果,包括临床改善和并发症.
主要方法:
- 预期组接受了50毫克的阿尔特等; 后期组接受了埃诺沙巴林.
- 主要结局:1个月和1年死亡率.
- 其次性结局:生命体征,出血,复发,CPTE,CTEPH.
主要成果:
- 阿尔特等治疗组的PaO2/FiO2比率显著改善,脉率下降.
- 在这两组中都没有发生重大出血.
- 一个月死亡率:6.7% (阿尔泰普拉斯) 与15.8% (埃诺沙巴林) 相比;一年死亡率:13.7%与26.3% (不具有统计学意义).
结论:
- 血栓溶解药物治疗改善了氧化和临床状态,没有重大并发症.
- 虽然阿尔特普拉斯的死亡率较低,但这种差异缺乏统计学意义.
- 需要进行更大规模的研究来证实PE小组中血栓消毒疗法的临床效用.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
911
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
911
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
44
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
44
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Pulmonary Embolism III: Nursing Management
42
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
42
Pulmonary Embolism I: Introduction
46
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
46
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K

